We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M
This Fund
S&P 500
This Quarter Est. Return
+2.42%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$141M
AUM Growth
+$26.9M
Cap. Flow
+$26.9M
Cap. Flow %
19.02%
Top 10 Hldgs %
81.88%
Holding
105
New
20
Increased
10
Reduced
43
Closed
26

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$35.6M
2
SERA icon
Sera Prognostics
SERA
+$6.17M
3
IRON icon
Disc Medicine
IRON
+$555K
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$535K
5
ARDX icon
Ardelyx
ARDX
+$529K

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$584K
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$554K
3
CGON icon
CG Oncology
CGON
+$552K
4
BLTE
Belite Bio
BLTE
+$551K
5
APLS
Apellis Pharmaceuticals
APLS
+$549K

Sector Composition

Rank Sector Weight
1 Healthcare 24.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$65.5B
$468K 0.33%
641
+11
+2% +$8.61K
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$1.79B
$467K 0.33%
20,000
-4,716
-19% -$102K
INBX icon
28
Inhibrx
INBX
$1.84B
$466K 0.33%
6,927
+538
+8% +$39.9K
ARQT icon
29
Arcutis Biotherapeutics
ARQT
$3.16B
$464K 0.33%
19,700
+984
+5% +$25.1K
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.61B
$463K 0.33%
+22,100
New +$498K
MIRM icon
31
Mirum Pharmaceuticals
MIRM
$6.01B
$462K 0.33%
5,000
-1,854
-27% -$174K
COGT icon
32
Cogent Biosciences
COGT
$6.37B
$462K 0.33%
12,000
-1,233
-9% -$45.5K
GLUE icon
33
Monte Rosa Therapeutics
GLUE
$1.23B
$461K 0.33%
+28,000
New +$535K
IMCR icon
34
Immunocore
IMCR
$1.91B
$457K 0.32%
15,141
+717
+5% +$23.2K
CRSP icon
35
CRISPR Therapeutics
CRSP
$5.73B
$452K 0.32%
9,500
-80
-0.8% -$4.22K
BBIO icon
36
BridgeBio Pharma
BBIO
$15.5B
$446K 0.32%
6,000
-1,140
-16% -$82.6K
NRIX icon
37
Nurix Therapeutics
NRIX
$2.77B
$445K 0.31%
28,700
-13
-0% -$216
AUPH icon
38
Aurinia Pharmaceuticals
AUPH
$2.2B
$445K 0.31%
30,000
-3,953
-12% -$57.8K
ACAD icon
39
Acadia Pharmaceuticals
ACAD
$5.1B
$440K 0.31%
19,766
– –
RAPP
40
Rapport Therapeutics
RAPP
$2.52B
$438K 0.31%
14,000
-3,506
-20% -$98.6K
IMNM icon
41
Immunome
IMNM
$3.27B
$437K 0.31%
20,000
-5,245
-21% -$117K
KNSA icon
42
Kiniksa Pharmaceuticals
KNSA
$6.14B
$433K 0.31%
9,000
-3,655
-29% -$162K
TGTX icon
43
TG Therapeutics
TGTX
$8.42B
$432K 0.31%
13,000
-4,807
-27% -$143K
DNTH icon
44
Dianthus Therapeutics
DNTH
$6.2B
$420K 0.3%
5,000
-7,725
-61% -$447K
CLDX icon
45
Celldex Therapeutics
CLDX
$3.19B
$412K 0.29%
13,000
-7,368
-36% -$201K
PTCT icon
46
PTC Therapeutics
PTCT
$6.07B
$409K 0.29%
6,000
-1,046
-15% -$74.1K
VERA icon
47
Vera Therapeutics
VERA
$2.65B
$402K 0.28%
10,000
+4
+0% +$172
HRMY icon
48
Harmony Biosciences
HRMY
$2.31B
$400K 0.28%
14,283
– –
CRNX icon
49
Crinetics Pharmaceuticals
CRNX
$9B
$400K 0.28%
11,000
-316
-3% -$14.1K
CMPS
50
Compass Pathways
CMPS
$2.02B
$393K 0.28%
+71,000
New +$477K
1
2
3 4 5

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
AIMA
Ables Iannone Moore & Associates Savannah, Georgia $188M AUM 26.75% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return

PSP Research's Q1 2026 Portfolio in Review

As of Q1 2026, PSP Research held 105 positions worth $141M, up 24% from $114M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

PSP Research deployed $26.9M of net new capital in Q1 2026, opening 20 new positions and adding to 10 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 284,900 shares worth $36.4M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 39% a quarter earlier.

On the sell side, the largest reduction was Amylyx Pharmaceuticals, an estimated $470K trimmed.

  • PSP Research's largest Q1 2026 buy was State Street SPDR S&P Biotech ETF: 284,900 shares worth $36.4M.
  • PSP Research added most to Alnylam Pharmaceuticals in Q1 2026, an estimated $50K increase.
  • PSP Research's biggest Q1 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $470K.
  • PSP Research fully exited Travere Therapeutics in Q1 2026, selling an estimated $584K.
  • PSP Research's ten largest holdings make up 82% of its $141M portfolio in Q1 2026.
  • PSP Research opened 20 new positions and closed 26 in Q1 2026.
  • PSP Research's portfolio value rose 24% quarter-over-quarter to $141M.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.